US Cancer Vaccine Pipeline Analysis

Publish Date:- Jan-2014      No Of Pages (300)

Electronic Access - Single User License $1500 Buy Now
CD-ROM Mail Delivery $1800Buy Now
Hard Copy Mail Delivery $2400 Buy Now
Electronic Access - Multi-User License $3000 Buy Now


Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. Merck’s Gardasil, a Prophylactic cancer vaccine, along with GSK’s Cervarix are some of the first vaccines to have gained attention globally with their blockbuster status.

The market for cancer vaccine is in its growth stage in the US and has great opportunities for entry. Constituting almost 50% of the global pie, the US cancer vaccine market was estimated to be worth USD 14 Billion in 2012. With close to 1.5 million Americans being diagnosed with cancer every year, this market is expected to o reach USD 20 billion by 2020.

US Cancer Vaccine Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various vaccines being developed for the treatment of various cancers. Research report covers all vaccines being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US cancer vaccine market based upon development process.

Following parameters for each orphan designated drug profile in development phase are covered in “US Cancer Vaccine Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



US Cancer Vaccine Pipeline by Clinical Phase:

• Research: 2

• Preclinical: 38

• Clinical: 2

• Phase-0: 1

• Phase-I: 35

• Phase-I/II: 19

• Phase-II: 32

• Phase-II/III: 2

• Phase-III: 17

• Marketed: 5


Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. Merck’s Gardasil, a Prophylactic cancer vaccine, along with GSK’s Cervarix are some of the first vaccines to have gained attention globally with their blockbuster status.

The market for cancer vaccine is in its growth stage in the US and has great opportunities for entry. Constituting almost 50% of the global pie, the US cancer vaccine market was estimated to be worth USD 14 Billion in 2012. With close to 1.5 million Americans being diagnosed with cancer every year, this market is expected to o reach USD 20 billion by 2020.

US Cancer Vaccine Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various vaccines being developed for the treatment of various cancers. Research report covers all vaccines being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US cancer vaccine market based upon development process.

Following parameters for each orphan designated drug profile in development phase are covered in “US Cancer Vaccine Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



US Cancer Vaccine Pipeline by Clinical Phase:

• Research: 2

• Preclinical: 38

• Clinical: 2

• Phase-0: 1

• Phase-I: 35

• Phase-I/II: 19

• Phase-II: 32

• Phase-II/III: 2

• Phase-III: 17

• Marketed: 5

1. US Cancer Vaccine Market Overview



2. US Cancer Vaccine Market Regulations

  2.1 Considerations for Both Early and Late Phase Clinical Trials

  2.2 Considerations for Early Phase Clinical Trials

  2.3 Considerations For Late Phase Clinical Trials



3. Cancer Vaccine Development Clinical Phase: Research

  3.1 Overview

  3.2 Cancer Vaccine Profile in Clinical Phase



4. Cancer Vaccine Development Clinical Phase: Preclinical

  4.1 Overview

  4.2 Cancer Vaccine Profile in Clinical Phase



5. Cancer Vaccine Development Clinical Phase: Clinical

  5.1 Overview

  5.2 Cancer Vaccine Profile in Clinical Phase



6. Cancer Vaccine Development Clinical Phase: Phase-0

  6.1 Overview

  6.2 Cancer Vaccine Profile in Clinical Phase



7. Cancer Vaccine Development Clinical Phase: Phase-I

  7.1 Overview

  7.2 Cancer Vaccine Profile in Clinical Phase



8. Cancer Vaccine Development Clinical Phase: Phase-I/II

  8.1 Overview

  8.2 Cancer Vaccine Profile in Clinical Phase



9. Cancer Vaccine Development Clinical Phase: Phase-II

  9.1 Overview

  9.2 Cancer Vaccine Profile in Clinical Phase



10. Cancer Vaccine Development Clinical Phase: Phase-II/III

  10.1 Overview

  10.2 Cancer Vaccine Profile in Clinical Phase



11. Cancer Vaccine Development Clinical Phase: Phase-III

  11.1 Overview

  11.2 Cancer Vaccine Profile in Clinical Phase



12. Marketed

  12.1 Overview

  12.2 Marketed Cancer Vaccine Profile


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC Code

• Designated Brand Name